Brief: China Grand Pharmaceutical And Healthcare Says Global Innovative Drug Ryaltris Compound Nasal Spray Granted Phase Three Clinical Trial Approval From Nmpa
20/10/2021 11:22
Oct 20 (Reuters) - China Grand Pharmaceutical and Healthcare
Holdings Ltd 0512.HK :
* GLOBAL INNOVATIVE DRUG RYALTRIS COMPOUND NASAL SPRAY
GRANTED
PHASE THREE CLINICAL TRIAL APPROVAL FROM NMPA
Source text for Eikon: ID:nHKSn6rgT
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement